Abstract Details

Title Guillain-Barre Syndrome after Influenza Vaccination in Adults

Topic Neuro Trauma and Critical Care

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 1-006

Background

GBS was reported after receiving influenza vaccination.

Objective

To investigate the association of Guillain-Barre syndrome (GBS) after administration of influenza vaccine in the United States.

Design/Methods Data from the Vaccine Adverse Event Reporting System (VAERS) from 1989-2021 was used. GBS data was ascertained using Brighton criteria. Self-controlled case series analysis and case-centered analysis were used. Six weeks after vaccination was defined as the risk period of probable cause-effect.

Results From 1989 to 2021, 3285 cases (mean age 47 years) of GBS fulfilling Brighton criteria and 663 cases that did not fulfill Brighton criteria were reported. The reporting rate of GBS after influenza vaccination was 0.09 per million. Among the patients fulfilling Brighton criteria, 82.1% developed GBS within 6 weeks and 17.9% after 6 weeks. The distribution of GBS within the first 6 weeks after vaccination was unbalanced: 59.4% of GBS cases were reported within the first two weeks with a peak in the first week after vaccination. Hospitalization and disability were reported in 9.6% and 19.2% cases, respectively. GBS occurred in 54.2% cases when the influenza vaccine was administrated as a single vaccine and in 0.8% cases when combined with other vaccines. Using self-controlled and case centered analyses, there was a significant difference in the reporting rate of GBS after influenza vaccination between the risk period and control period (86.8% vs 2.2-7.1%, p<0.00001).

Conclusions There is no significant increase in the reporting rate of GBS after vaccination. Although, our results suggest that the reporting rate of GBS post-influenza vaccine overlaps with the incidence of GBS in the general population, the unbalanced distribution of reported cases in the first 6 weeks after vaccination and the increased reporting rate in the risk time period compared to the control time period may suggest that some cases of GBS are associated with influenza vaccine.

Authors/Disclosures
PRESENTER	No disclosure on file
Mustafa Jaffry	Mr. Jaffry has nothing to disclose.
Kranthi K. Mandava	Mr. Mandava has nothing to disclose.
Kazim Jaffry	Mr. Jaffry has nothing to disclose.
Jorge L. Rodriguez Lee, MD (Yale School of Medicine)	Dr. Rodriguez Lee has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Ayatalla Ahmed, MBBS	Dr. Ahmed has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received publishing royalties from a publication relating to health care.